A bill for an act relating to insurance coverage for prescription insulin drugs.
Summary
Senate File 209 would require certain health insurance policies, health maintenance organization contracts, and public employee health plans that cover prescription drugs to cap a covered person’s out-of-pocket cost-sharing for insulin at no more than $25 per prescription fill for up to a 31-day supply. The cap would apply to at least one type of each major insulin category: rapid-acting, short-acting, intermediate-acting, and long-acting insulin. The bill defines prescription insulin drugs as medically necessary insulin prescribed by a health care professional and covered under the person’s plan.
The bill also specifies that insurers may charge less than the $25 cap, but not more, and it authorizes the Iowa insurance commissioner to adopt rules to administer the new requirements. The mandate would apply to policies and plans delivered, issued, continued, or renewed in Iowa on or after January 1, 2026, while excluding several categories of coverage such as accident-only, short-term, Medicare supplement, long-term care, dental, vision, workers’ compensation, and automobile medical payment coverage.
Impact
SF 209 would amend Iowa insurance law by creating a new section in chapter 514C that limits insulin-related cost-sharing in covered prescription drug plans. It would directly affect individual and group health insurance, hospital and medical service contracts, HMOs, and the state public employee health plan, while leaving many specialized or limited-benefit policies outside the mandate. The practical effect would be to reduce out-of-pocket insulin costs for insured people with diabetes and require insurers and plan administrators to adjust benefit design, claims processing, and compliance practices for policies renewed or issued on or after the effective applicability date.
Sentiment
The available context suggests generally favorable or at least supportive treatment of the bill, as indicated by its introduction with multiple bipartisan-sounding sponsors and referral to subcommittee without recorded opposition in the provided materials. Because there are no committee transcripts or votes included, there is no documented debate to show formal support or resistance. The bill’s structure and subject matter indicate a consumer-protection and affordability focus, which typically draws support from advocates for patients with diabetes and lower prescription drug costs.
Contention
The main policy tension is between lowering insulin costs for patients and imposing a mandated benefit on insurers and health plans. Potential concerns would likely center on premium impacts, the scope of the mandate, and whether the $25 cap should apply more broadly or be limited to certain plan types and insulin formulations. Another possible point of contention is the delayed applicability date of January 1, 2026, which gives insurers time to adjust but may be viewed by supporters as postponing relief. No specific objections or amendments are documented in the provided record.